Caplight Directory>Companies>GEn1E Lifesciences-preview>Gen1e-lifesciences


GEn1E Lifesciences

GEn1E Lifesciences

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.gen1e.com

Last Round

Series A

Dec 21, 2022

Total Funding Raised

$20.03M

Momentum Score

50 /100

Company Overview

GEn1E Lifesciences is a biotechnology company that accelerates the development of next-generation immunomodulatory therapies for rare and inflammatory diseases through an innovative drug development platform that leverages artificial intelligence to create novel therapeutics rapidly.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting, Revenue Share

AI Layer

Application

Keywords

AI drug discoverytechbiokinase inhibitorsinflammatory diseasesAcute Respiratory Distress SyndromeARDSAI biotechdrug discovery platformclinical-stage biotechcomputational drug discoveryimmunomodulatorsimmuno-oncologyin silico drug discoveryrare diseasesp38α:MK2 modulatorBARDA contract

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GEn1E Lifesciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GEn1E Lifesciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ADec 21, 2022
SeedMar 31, 2020
View all Funding Rounds

Key People

Founding team and executive leadership

Ritu Lal

CEO And Co-Founder

Founding Team

GEn1E Lifesciences Investors

Notable investors and investment history

InvestorRounds
Khosla VenturesSeed, Series A
Inflect HealthSeed, Series A
Clear VenturesSeed, Series A
Y CombinatorSeed, Series A
SV Latam CapitalSeed, Series A
View all Investors

GEn1E Lifesciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GEn1E Lifesciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GEn1E Lifesciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range18
Year Founded2018
Last FundingDec 21, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.